Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial
Year: 2026
Type: article
Source: UNC Libraries
DOI: 10.17615/pwgf-9a79
Authors: Spiegel, Hans, Tomaras, Georgia D, Piwowar-Manning, Estelle, Miner, Maurine D, Paez, Carmen A, Weiner, Joshua A, Corey, Lawrence, Heptinstall, Jack, Proulx-Burns, Lori, Yacovone, Margaret, Kelley, Colleen F, Scott, Hyman, Bailey, Veronique C, Takuva, Simbarashe, McElrath, M Juliana, Yu, Chenchen, Dye, Bonnie, Huang, Yunda, Seaton, Kelly E, Barouch, Dan H, Montefiori, David, Dumond, Julie B, Tindale, India, Karuna, Shelly T, Zhang, Lu, Gao, Fei, Mahomed, Sharana, Takalani, Azwidihwi, Trahey, Meg, Kalams, Spyros A, Siegel, Marc, team, HVTN 140/HPTN 101 study, Mkhize, Nonhlanhla N, Anderson, Maija, Cohen, Myron S, Ackerman, Margaret E, Pensiero, Michael, Gamble, Theresa
Institution: University of North Carolina at Chapel Hill
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7160448645